NeuroBo Pharmaceuticals, Inc.
NASDAQ:NRBO
Overview | Financials
Company Name | NeuroBo Pharmaceuticals, Inc. |
Symbol | NRBO |
Currency | USD |
Price | 2.88 |
Market Cap | 24,441,984 |
Dividend Yield | 0% |
52-week-range | 2.08 - 6.75 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Hyung-Heon Kim |
Website | https://www.neurobopharma.com |
An error occurred while fetching data.
About NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD